Remote patient monitoring is one of the areas of healthcare that has seen widespread adoption in recent years, with more seniors opting for home care, partly because of the pandemic, but also because CMS introduces reimbursement codes Improve monitoring of chronic diseases such as heart disease and diabetes.
exist Medical City Investment The launch event will be held March 28-30 at the Ritz-Carlton, Chicago, where 10 companies will compete in the remote patent monitoring and smart device track of the four-track Pitch Perfect competition. Focusing on innovative topics in healthcare, the conference includes healthcare executives, startups and investors.
To view the full agenda, Click here.
The track’s judges include:
Here are the participating companies:
11 Health and Technology Created the first digitally connected ostomy wearable device that supports sensors to provide actionable insights for patients and remote monitoring for clinicians to reduce the incidence and severity of common complications in ostomy patients. The company has demonstrated an 80% reduction in 30-day readmissions and a 66% reduction in 30-day emergency room visits. The company is raising capital to kick-start its commercialization program, while signing new contracts with Illinois-based Blue Cross Blue Shield and Universal Care, and funding a value-based pilot program with the business’ leading insurer.
Brumio Health monitoring is being transformed with a wearable sensor that continuously measures blood pressure non-invasively. The company’s key innovation is the use of radar to directly measure arterial wall motion and measure vital signs. The first application is in maternal care, where 1 in 25 expecting mothers develop preeclampsia. In the United States, this condition is responsible for 40% of unwanted preterm births and 10,500 infant deaths each year. As a reimbursable remote patient monitoring solution prescribed through OB/GYN, Blumio’s predictive analytics engine identifies blood pressure abnormalities and monitors the onset of preeclampsia throughout pregnancy. Founded in 2016, Blumio provides risk support and support from medical consultants with expertise in cardiology, anesthesiology and emergency medicine. The company has been accredited by the American College of Cardiology, as well as research grants from the National Science Foundation and the Centers for Disease Control.
Electronic reception is a deep tech company headquartered in Cambridge, UK, paving the way for personalised digital healthcare by developing novel chronic disease management solutions. Its algorithms enable the company to extract medical-grade vital signs and insights into cardiovascular and respiratory function from only smartphone sensors, without the need for additional hardware. It has an interdisciplinary team of scientists and engineers from leading academic research organisations working in partnership with an international consortium of clinicians to put the power to gather physiological health insights into the hands of 6 billion people around the world. To this end, the company seeks to transform the way healthcare is delivered and disease treated by creating digital therapeutics that enable proactive, preventative care and inform personalized interventions in real time. Initial focus on cardiovascular disease; expand cost-effective tools to improve the 82.6 million cardiovascular Disease detection and management of patients with disease.
Ancora Treatment Smart wearables are being developed that can track tremor progression and provide real-time personalized hand tremor relief for individuals with neuromotor disorders such as Parkinson’s disease and essential tremor — all without side effects or tremors management burden.
LCP Medical Technology is a young company with 25 years of experience in the semiconductor and printed circuit industry. Its advanced manufacturing technology could help make such devices better and 50% to 200% smaller through more precise measurements, improved battery management and secure wireless communications, and a generational roadmap. The core technology allows making the circuits used in these types of devices smaller, while embedding the sensors for direct use in liquid crystal polymers, one of the only biocompatible materials that can be implanted or worn. With 67 patents and a $5 million investment program, the company aims to build fast turnaround first-article products with volume manufacturing partners to support such devices from startups to industry leaders.
Neurology Create innovative wearable devices that provide comprehensive personalized diagnosis and treatment for people with balance disorders due to aging, injury or disease. Age-related balance disorders caused by vestibular dysfunction affect 35% of U.S. adults 40 years and older (58 million Americans), and injury and illness can accelerate the onset of balance disorders. The economic burden in the U.S. exceeds $250 billion Currently, diagnosing these disruptions requires expensive clinical equipment and complex procedures unavailable to most patients, while treatment to restore balance requires surgically implanted electrodes. Neursantys has developed Neurvesta, a non-invasive wearable device that allows clinicians to screen for damage to the vestibular balance system and then apply corrective neurostimulation to help restore disrupted balance. Neurvesta devices and related services are positioned to be the cornerstone of the $150 billion annual U.S. aging-in-place market
NXgenPort Corporation Unmet needs in cancer care are being addressed by implanted smart ports to remotely monitor patients between chemotherapy visits. By measuring cell counts, vital signs and heart function in vivo, NGP will alert physicians to signs of infection, reduce hospitalizations, and collect vital physiological data to improve patient outcomes. For cancer researchers and drug delivery stakeholders, there is additional value in remotely monitoring participants’ biological responses to interventions.
Reos is a venture-backed clinical-stage medical device company developing FlowSense, a platform technology and a non-invasive wireless, wearable skin patch that assesses and monitors fluid flow around the body. The company’s initial target was hydrocephalus, a life-threatening condition caused by an abnormal buildup of cerebrospinal fluid (CSF). Implantable shunts, the gold standard of care, often fail, leading to multiple trips to the emergency room and repeated surgeries. There is currently no technology available that can wirelessly, bedside easily assess CSF flow in a shunt without fixed equipment. Rhaeos has raised more than $8 million in financing, received breakthrough designation from the FDA, published clinical data in the Science and Nature series of journals, and is on track to enter the market for the first time in 2022. The company is currently raising $6 million in Series A funding.
Swing Medical is an FDA-approved digital assessment platform for assessing balance, cognition, functional performance and fall risk. Assessments on the Sway platform require only a dedicated iPad in the clinic or the patient’s own smartphone device and can be completed in minutes. Sway’s technology utilizes the built-in sensors of any mobile device to provide accurate measurements of postural stability and functional movement simply by pressing the device against the chest and completing standardized protocols. Sway provides objective measurements by replacing expensive force platforms, motion capture systems and subjective screening procedures with an integrated digital solution that collects objective data using inexpensive smart devices.
Weihualian Provides digital healthcare solutions for patient monitoring, virtual care and decentralized clinical trials. The company’s robust biometric data platform enables healthcare solution providers to rapidly build and scale their technology across any therapeutic area. The platform includes wearable medical-grade sensors and IoT cloud software that continuously captures human vital signs and biometrics to accelerate the development and deployment of healthcare applications. Its unique platform leverages physiologically optimized medical wearable sensors and cloud data services to enable deeper, more clinical understanding between providers and patients.
picture: Kento, Getty Images
